Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 1 | 2023 | 572 | 0.570 |
Why?
|
| Digital Rectal Examination | 1 | 2014 | 42 | 0.460 |
Why?
|
| Radiosurgery | 4 | 2019 | 1330 | 0.460 |
Why?
|
| Radiotherapy, Conformal | 2 | 2014 | 545 | 0.400 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2012 | 164 | 0.350 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2009 | 422 | 0.320 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 392 | 0.270 |
Why?
|
| Adenoma | 2 | 2014 | 2155 | 0.260 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 945 | 0.250 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 1324 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2012 | 1097 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 2463 | 0.230 |
Why?
|
| Disease Management | 1 | 2014 | 2533 | 0.210 |
Why?
|
| Automation | 1 | 2023 | 586 | 0.180 |
Why?
|
| Prescriptions | 1 | 2023 | 388 | 0.180 |
Why?
|
| Skin Neoplasms | 3 | 2019 | 5860 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 2426 | 0.160 |
Why?
|
| Benzoquinones | 2 | 2009 | 198 | 0.150 |
Why?
|
| Lactams, Macrocyclic | 2 | 2009 | 319 | 0.140 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2018 | 180 | 0.130 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2025 | 1673 | 0.130 |
Why?
|
| Breast Neoplasms | 4 | 2014 | 21162 | 0.130 |
Why?
|
| Medical Errors | 1 | 2023 | 1260 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2009 | 5690 | 0.120 |
Why?
|
| Cisplatin | 1 | 2021 | 1656 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15912 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 2025 | 2171 | 0.120 |
Why?
|
| Endometrial Neoplasms | 2 | 2014 | 1381 | 0.110 |
Why?
|
| Tumor Burden | 3 | 2018 | 1902 | 0.110 |
Why?
|
| Radiotherapy Dosage | 3 | 2019 | 2916 | 0.110 |
Why?
|
| Cysts | 1 | 2019 | 685 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 865 | 0.110 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 9101 | 0.100 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 974 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 11094 | 0.100 |
Why?
|
| Parathyroid Neoplasms | 1 | 2012 | 244 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2014 | 504 | 0.090 |
Why?
|
| Parathyroidectomy | 1 | 2012 | 244 | 0.090 |
Why?
|
| Photons | 1 | 2014 | 591 | 0.090 |
Why?
|
| Muscle Weakness | 1 | 2012 | 412 | 0.080 |
Why?
|
| Palliative Care | 1 | 2025 | 3640 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 754 | 0.080 |
Why?
|
| Receptors, Growth Factor | 1 | 2009 | 324 | 0.080 |
Why?
|
| Kidney Calculi | 1 | 2012 | 458 | 0.080 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2008 | 147 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 9407 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 2077 | 0.070 |
Why?
|
| Receptor, erbB-3 | 1 | 2008 | 141 | 0.070 |
Why?
|
| Serum | 1 | 2008 | 206 | 0.070 |
Why?
|
| Cricetulus | 1 | 2008 | 810 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2012 | 1069 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1791 | 0.060 |
Why?
|
| CHO Cells | 1 | 2008 | 1376 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2012 | 1497 | 0.060 |
Why?
|
| Fatigue | 1 | 2012 | 1555 | 0.060 |
Why?
|
| Retrospective Studies | 8 | 2025 | 81657 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2014 | 6329 | 0.060 |
Why?
|
| Cricetinae | 1 | 2008 | 2416 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 2882 | 0.060 |
Why?
|
| DNA Repair | 1 | 2014 | 2050 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2008 | 3587 | 0.060 |
Why?
|
| Humans | 21 | 2025 | 766812 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 1062 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5389 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 4050 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2009 | 2456 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 11218 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 39312 | 0.050 |
Why?
|
| Risk | 1 | 2014 | 9602 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2025 | 54872 | 0.050 |
Why?
|
| Middle Aged | 9 | 2021 | 223267 | 0.050 |
Why?
|
| Quinazolines | 1 | 2008 | 1367 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2009 | 1621 | 0.050 |
Why?
|
| Salvage Therapy | 2 | 2018 | 1274 | 0.050 |
Why?
|
| Indoles | 1 | 2009 | 1834 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 8623 | 0.050 |
Why?
|
| Aged | 6 | 2021 | 171344 | 0.040 |
Why?
|
| Skin | 1 | 2014 | 4499 | 0.040 |
Why?
|
| Female | 12 | 2025 | 396532 | 0.040 |
Why?
|
| Genome, Human | 1 | 2013 | 4443 | 0.040 |
Why?
|
| Recurrence | 1 | 2012 | 8507 | 0.040 |
Why?
|
| Calcium | 1 | 2012 | 5783 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2009 | 1982 | 0.040 |
Why?
|
| Piperazines | 1 | 2009 | 2547 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2019 | 65286 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 896 | 0.040 |
Why?
|
| Spinal Neoplasms | 1 | 2025 | 714 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2001 | 635 | 0.040 |
Why?
|
| Male | 8 | 2025 | 364154 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8540 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 13489 | 0.040 |
Why?
|
| Spine | 1 | 2025 | 1134 | 0.040 |
Why?
|
| Adult | 5 | 2021 | 223305 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 4523 | 0.030 |
Why?
|
| Erythema | 1 | 2018 | 261 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2020 | 5306 | 0.030 |
Why?
|
| Hyperpigmentation | 1 | 2018 | 116 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 17089 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 1244 | 0.030 |
Why?
|
| Apoptosis | 2 | 2009 | 9514 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 59548 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 12064 | 0.030 |
Why?
|
| Young Adult | 3 | 2021 | 59939 | 0.030 |
Why?
|
| Fat Necrosis | 1 | 2014 | 60 | 0.030 |
Why?
|
| Radiodermatitis | 1 | 2014 | 61 | 0.030 |
Why?
|
| Telangiectasis | 1 | 2014 | 78 | 0.030 |
Why?
|
| Necrosis | 1 | 2018 | 1614 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 1788 | 0.030 |
Why?
|
| Algorithms | 2 | 2025 | 14073 | 0.030 |
Why?
|
| Depression | 1 | 2012 | 8225 | 0.030 |
Why?
|
| Neoplasms | 2 | 2014 | 22350 | 0.030 |
Why?
|
| DNA Polymerase II | 1 | 2013 | 103 | 0.030 |
Why?
|
| Mastectomy | 1 | 2021 | 1861 | 0.030 |
Why?
|
| Skin Pigmentation | 1 | 2014 | 278 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2013 | 23618 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2018 | 2659 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2001 | 1836 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 13644 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2018 | 1195 | 0.020 |
Why?
|
| Animals | 3 | 2014 | 168939 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 41706 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2014 | 716 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1594 | 0.020 |
Why?
|
| Protein Kinase C-delta | 1 | 2009 | 115 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 2662 | 0.020 |
Why?
|
| Hippocampus | 1 | 2020 | 3776 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 6514 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1925 | 0.020 |
Why?
|
| DNA Replication | 1 | 2014 | 1426 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 1776 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2014 | 1407 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2009 | 562 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 872 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2009 | 1088 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 4114 | 0.010 |
Why?
|
| Child | 1 | 2012 | 80670 | 0.010 |
Why?
|
| DNA Copy Number Variations | 1 | 2013 | 2045 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 88902 | 0.010 |
Why?
|
| Survival Rate | 1 | 2018 | 12826 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 12536 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 6105 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 3485 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2025 | 20710 | 0.010 |
Why?
|
| Threonine | 1 | 2001 | 272 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2001 | 330 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2001 | 694 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2001 | 1677 | 0.010 |
Why?
|
| Genomics | 1 | 2013 | 5922 | 0.010 |
Why?
|
| Tyrosine | 1 | 2001 | 1425 | 0.010 |
Why?
|
| Time Factors | 1 | 2018 | 40149 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 4903 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 9613 | 0.010 |
Why?
|
| Point Mutation | 1 | 2001 | 1592 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2001 | 3053 | 0.010 |
Why?
|
| United States | 1 | 2022 | 72945 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 5022 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2013 | 12159 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 29959 | 0.010 |
Why?
|
| HIV Infections | 1 | 2019 | 17532 | 0.010 |
Why?
|
| Brain | 1 | 2018 | 27158 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2001 | 2678 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12415 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2001 | 8310 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 13411 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 17609 | 0.000 |
Why?
|
| Rats | 1 | 2001 | 23717 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 81898 | 0.000 |
Why?
|
Concepts
(167)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(67)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_